NCT05819112View on ClinicalTrials.gov

A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness

TerminatedOBSERVATIONAL
Enrollment

14,799

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

December 15, 2023

Study Completion Date

December 15, 2023

Conditions
Venous Thromboembolism
Trial Locations (1)

08807

Sanofi U.S., Bridgewater

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT05819112 - A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness | Biotech Hunter | Biotech Hunter